NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) announced that its board compensation committee granted stock options to purchase an aggregate of 120,000 shares of common stock to nine newly hired employees on February 12, 2026.
The company said the awards were issued under its 2025 New Hire Inducement Plan as a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
According to the release, the stock options will vest over a four-year period.
Orchestra BioMed said it disclosed the awards pursuant to Nasdaq listing requirements.
The company is a biomedical firm focused on advancing medical technologies through strategic collaborations with global medical device companies. Its lead product candidates include Atrioventricular Interval Modulation Therapy, a bioelectronic treatment for hypertension being developed in collaboration with Medtronic, and the Virtue Sirolimus AngioInfusion Balloon system for the treatment of atherosclerotic artery disease.
Orchestra BioMed is headquartered in New Hope.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.